PMC:7228307 / 47488-49159
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id | tao:has_standard_notation |
---|---|---|---|---|---|---|
914 | 359-367 | Gene | denotes | FcγRIIIa | Gene:2214 | |
915 | 403-411 | Gene | denotes | FcγRIIIa | Gene:2214 | |
916 | 449-456 | Gene | denotes | FcγRIII | Gene:14131 | |
917 | 529-534 | Species | denotes | mouse | Tax:10090 | |
918 | 240-268 | Disease | denotes | chronic lymphocytic leukemia | MESH:D015451 | |
919 | 502-525 | Disease | denotes | reduced lymphoma growth | MESH:D006130 | |
920 | 314-319 | Mutation | denotes | S329D | p.S329D | |
921 | 324-329 | Mutation | denotes | I332E | p.I332E | |
941 | 624-628 | Gene | denotes | HER2 | Gene:2064 | |
942 | 662-666 | Gene | denotes | HER2 | Gene:2064 | |
943 | 783-791 | Gene | denotes | FcγRIIIa | Gene:2214 | |
944 | 869-876 | Gene | denotes | FcγRIIb | Gene:2213 | |
945 | 1030-1034 | Gene | denotes | HER2 | Gene:13866 | |
946 | 1101-1105 | Gene | denotes | HER2 | Gene:13866 | |
947 | 911-915 | Gene | denotes | FcγR | Gene:2213 | |
948 | 1132-1136 | Species | denotes | mice | Tax:10090 | |
949 | 543-555 | Chemical | denotes | Margetuximab | MESH:C000617981 | |
950 | 633-644 | Chemical | denotes | trastuzumab | MESH:D000068878 | |
951 | 971-982 | Chemical | denotes | trastuzumab | MESH:D000068878 | |
952 | 988-1000 | Chemical | denotes | margetuximab | MESH:C000617981 | |
953 | 678-685 | Disease | denotes | cancers | MESH:D009369 | |
954 | 1117-1122 | Disease | denotes | tumor | MESH:D009369 | |
955 | 725-730 | Mutation | denotes | L235V | p.L235V | |
956 | 732-737 | Mutation | denotes | F243L | p.F243L | |
957 | 739-744 | Mutation | denotes | R292P | p.R292P | |
958 | 746-751 | Mutation | denotes | Y300L | p.Y300L | |
959 | 756-761 | Mutation | denotes | P396L | p.P396L | |
967 | 1445-1453 | Gene | denotes | FcγRIIIa | Gene:2214 | |
968 | 1152-1164 | Chemical | denotes | ocaratuzumab | MESH:C550337 | |
969 | 1256-1263 | Disease | denotes | cancers | MESH:D009369 | |
970 | 1275-1295 | Disease | denotes | non‐Hodgkin lymphoma | MESH:D008228 | |
971 | 1300-1328 | Disease | denotes | chronic lymphocytic leukemia | MESH:D015451 | |
972 | 1350-1355 | Mutation | denotes | P247I | p.P247I | |
973 | 1360-1365 | Mutation | denotes | A339Q | p.A339Q | |
976 | 1572-1580 | Gene | denotes | FcγRIIIa | Gene:2214 | |
977 | 1552-1558 | Chemical | denotes | glycan | MESH:D011134 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T385 | 19-30 | Body_part | denotes | amino acids | http://purl.org/sig/ont/fma/fma82739 |
T386 | 49-60 | Body_part | denotes | amino acids | http://purl.org/sig/ont/fma/fma82739 |
T387 | 93-96 | Body_part | denotes | IgG | http://purl.org/sig/ont/fma/fma62872 |
T388 | 158-166 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
T389 | 248-259 | Body_part | denotes | lymphocytic | http://purl.org/sig/ont/fma/fma62863 |
T390 | 712-723 | Body_part | denotes | amino acids | http://purl.org/sig/ont/fma/fma82739 |
T391 | 1036-1041 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
T392 | 1308-1319 | Body_part | denotes | lymphocytic | http://purl.org/sig/ont/fma/fma62863 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T84 | 240-268 | Disease | denotes | chronic lymphocytic leukemia | http://purl.obolibrary.org/obo/MONDO_0004948 |
T85 | 248-268 | Disease | denotes | lymphocytic leukemia | http://purl.obolibrary.org/obo/MONDO_0005402 |
T86 | 260-268 | Disease | denotes | leukemia | http://purl.obolibrary.org/obo/MONDO_0005059 |
T87 | 466-470 | Disease | denotes | ADCC | http://purl.obolibrary.org/obo/MONDO_0008734 |
T88 | 510-518 | Disease | denotes | lymphoma | http://purl.obolibrary.org/obo/MONDO_0005062 |
T89 | 562-566 | Disease | denotes | ADCC | http://purl.obolibrary.org/obo/MONDO_0008734 |
T90 | 1017-1021 | Disease | denotes | ADCC | http://purl.obolibrary.org/obo/MONDO_0008734 |
T91 | 1117-1122 | Disease | denotes | tumor | http://purl.obolibrary.org/obo/MONDO_0005070 |
T92 | 1275-1295 | Disease | denotes | non‐Hodgkin lymphoma | http://purl.obolibrary.org/obo/MONDO_0011508|http://purl.obolibrary.org/obo/MONDO_0018908 |
T94 | 1279-1295 | Disease | denotes | Hodgkin lymphoma | http://purl.obolibrary.org/obo/MONDO_0004952 |
T95 | 1287-1295 | Disease | denotes | lymphoma | http://purl.obolibrary.org/obo/MONDO_0005062 |
T96 | 1300-1328 | Disease | denotes | chronic lymphocytic leukemia | http://purl.obolibrary.org/obo/MONDO_0004948 |
T97 | 1308-1328 | Disease | denotes | lymphocytic leukemia | http://purl.obolibrary.org/obo/MONDO_0005402 |
T98 | 1320-1328 | Disease | denotes | leukemia | http://purl.obolibrary.org/obo/MONDO_0005059 |
T99 | 1483-1487 | Disease | denotes | ADCC | http://purl.obolibrary.org/obo/MONDO_0008734 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T816 | 16-18 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T817 | 80-82 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T818 | 126-136 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activating |
T819 | 137-139 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T820 | 140-142 | http://purl.obolibrary.org/obo/CLO_0008882 | denotes | Rs |
T821 | 153-157 | http://purl.obolibrary.org/obo/CLO_0053432 | denotes | CD19 |
T822 | 310-312 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T823 | 359-361 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T824 | 403-405 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T825 | 449-451 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T826 | 529-534 | http://purl.obolibrary.org/obo/CLO_0007836 | denotes | mouse |
T827 | 581-583 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T828 | 783-785 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T829 | 869-871 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T830 | 904-905 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T831 | 911-913 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T832 | 1036-1050 | http://purl.obolibrary.org/obo/CL_0001034 | denotes | cells in vitro |
T833 | 1171-1173 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T834 | 1245-1246 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T835 | 1329-1331 | http://purl.obolibrary.org/obo/CLO_0001527 | denotes | 94 |
T836 | 1336-1338 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T837 | 1445-1447 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T838 | 1539-1541 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T839 | 1572-1574 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T840 | 1592-1593 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T240 | 19-30 | Chemical | denotes | amino acids | http://purl.obolibrary.org/obo/CHEBI_33709 |
T241 | 19-24 | Chemical | denotes | amino | http://purl.obolibrary.org/obo/CHEBI_46882 |
T242 | 25-30 | Chemical | denotes | acids | http://purl.obolibrary.org/obo/CHEBI_37527 |
T243 | 49-60 | Chemical | denotes | amino acids | http://purl.obolibrary.org/obo/CHEBI_33709 |
T244 | 49-54 | Chemical | denotes | amino | http://purl.obolibrary.org/obo/CHEBI_46882 |
T245 | 55-60 | Chemical | denotes | acids | http://purl.obolibrary.org/obo/CHEBI_37527 |
T246 | 712-723 | Chemical | denotes | amino acids | http://purl.obolibrary.org/obo/CHEBI_33709 |
T247 | 712-717 | Chemical | denotes | amino | http://purl.obolibrary.org/obo/CHEBI_46882 |
T248 | 718-723 | Chemical | denotes | acids | http://purl.obolibrary.org/obo/CHEBI_37527 |
LitCovid-sample-PD-IDO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T223 | 519-525 | http://purl.obolibrary.org/obo/GO_0040007 | denotes | growth |
T224 | 1036-1041 | http://purl.obolibrary.org/obo/CL_0000000 | denotes | cells |
LitCovid-sample-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T51 | 19-30 | Chemical | denotes | amino acids | http://purl.obolibrary.org/obo/CHEBI_33709 |
T52 | 49-60 | Chemical | denotes | amino acids | http://purl.obolibrary.org/obo/CHEBI_33709 |
T53 | 712-723 | Chemical | denotes | amino acids | http://purl.obolibrary.org/obo/CHEBI_33709 |
LitCovid-sample-Pubtator
Id | Subject | Object | Predicate | Lexical cue | pubann:denotes | pubann:has_HGVS_notation |
---|---|---|---|---|---|---|
914 | 359-367 | Gene | denotes | FcγRIIIa | Gene:2214 | |
915 | 403-411 | Gene | denotes | FcγRIIIa | Gene:2214 | |
916 | 449-456 | Gene | denotes | FcγRIII | Gene:14131 | |
917 | 529-534 | Species | denotes | mouse | Tax:10090 | |
918 | 240-268 | Disease | denotes | chronic lymphocytic leukemia | MESH:D015451 | |
919 | 502-525 | Disease | denotes | reduced lymphoma growth | MESH:D006130 | |
920 | 314-319 | Mutation | denotes | S329D | p.S329D | |
921 | 324-329 | Mutation | denotes | I332E | p.I332E | |
941 | 624-628 | Gene | denotes | HER2 | Gene:2064 | |
942 | 662-666 | Gene | denotes | HER2 | Gene:2064 | |
943 | 783-791 | Gene | denotes | FcγRIIIa | Gene:2214 | |
944 | 869-876 | Gene | denotes | FcγRIIb | Gene:2213 | |
945 | 1030-1034 | Gene | denotes | HER2 | Gene:13866 | |
946 | 1101-1105 | Gene | denotes | HER2 | Gene:13866 | |
947 | 911-915 | Gene | denotes | FcγR | Gene:2213 | |
948 | 1132-1136 | Species | denotes | mice | Tax:10090 | |
949 | 543-555 | Chemical | denotes | Margetuximab | MESH:C000617981 | |
950 | 633-644 | Chemical | denotes | trastuzumab | MESH:D000068878 | |
951 | 971-982 | Chemical | denotes | trastuzumab | MESH:D000068878 | |
952 | 988-1000 | Chemical | denotes | margetuximab | MESH:C000617981 | |
953 | 678-685 | Disease | denotes | cancers | MESH:D009369 | |
954 | 1117-1122 | Disease | denotes | tumor | MESH:D009369 | |
955 | 725-730 | Mutation | denotes | L235V | p.L235V | |
956 | 732-737 | Mutation | denotes | F243L | p.F243L | |
957 | 739-744 | Mutation | denotes | R292P | p.R292P | |
958 | 746-751 | Mutation | denotes | Y300L | p.Y300L | |
959 | 756-761 | Mutation | denotes | P396L | p.P396L | |
967 | 1445-1453 | Gene | denotes | FcγRIIIa | Gene:2214 | |
968 | 1152-1164 | Chemical | denotes | ocaratuzumab | MESH:C550337 | |
969 | 1256-1263 | Disease | denotes | cancers | MESH:D009369 | |
970 | 1275-1295 | Disease | denotes | non‐Hodgkin lymphoma | MESH:D008228 | |
971 | 1300-1328 | Disease | denotes | chronic lymphocytic leukemia | MESH:D015451 | |
972 | 1350-1355 | Mutation | denotes | P247I | p.P247I | |
973 | 1360-1365 | Mutation | denotes | A339Q | p.A339Q | |
976 | 1572-1580 | Gene | denotes | FcγRIIIa | Gene:2214 | |
977 | 1552-1558 | Chemical | denotes | glycan | MESH:D011134 |
LitCovid-sample-PD-NCBITaxon
Id | Subject | Object | Predicate | Lexical cue | ncbi_taxonomy_id |
---|---|---|---|---|---|
T44 | 529-534 | Species | denotes | mouse | NCBItxid:10090|NCBItxid:10088 |
T46 | 1132-1136 | Species | denotes | mice | NCBItxid:10095|NCBItxid:10088 |
LitCovid-sample-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T274 | 0-30 | Sentence | denotes | Mutation of the Fc amino acids |
T275 | 31-143 | Sentence | denotes | Alteration of the amino acids in the heavy‐chain Fc can alter IgG specificity and affinity for activating FcγRs. |
T276 | 144-424 | Sentence | denotes | The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele. |
T277 | 425-542 | Sentence | denotes | The mAb shows increased FcγRIII‐mediated ADCC and phagocytosis in vitro, and reduced lymphoma growth in mouse models. |
T278 | 543-922 | Sentence | denotes | Margetuximab is an ADCC‐enhanced IgG1 Fc‐engineered variant of the approved anti‐HER2 mAb trastuzumab in phase III for HER2‐expressing cancers.66, 93 Alteration of five amino acids (L235V, F243L, R292P, Y300L and P396L) enhanced binding to FcγRIIIa which also had the additional effect of decreasing binding to the inhibitory FcγRIIb, and thereby increased its A‐to‐I FcγR ratio. |
T279 | 923-1137 | Sentence | denotes | This was apparent when compared with unmodified trastuzumab the margetuximab showed enhanced ADCC against HER2+ cells in vitro and demonstrated superior antitumor effects in an HER2‐expressing tumor model in mice. |
T280 | 1138-1509 | Sentence | denotes | The anti‐CD20 ocaratuzumab is an Fc‐engineered IgG1 mAb in late‐stage clinical trials for the treatment of a range of cancers, including non‐Hodgkin lymphoma and chronic lymphocytic leukemia.94 Two Fc mutations, P247I and A339Q, conferred about 20‐fold increase in binding to both major allelic variants of FcγRIIIa and elicited sixfold greater ADCC than unmodified IgG1. |
T281 | 1510-1671 | Sentence | denotes | Thus, the engineering of the Fc domain or glycan for improved FcγRIIIa binding is a powerful tool to create more potent and clinically effective anticancer mAbs. |
LitCovid-sample-UniProt
Id | Subject | Object | Predicate | Lexical cue | uniprot_id |
---|---|---|---|---|---|
T596 | 153-157 | Protein | denotes | CD19 | https://www.uniprot.org/uniprot/Q9BRD6|https://www.uniprot.org/uniprot/Q96S68|https://www.uniprot.org/uniprot/Q542B2|https://www.uniprot.org/uniprot/Q3LRP3|https://www.uniprot.org/uniprot/P25918|https://www.uniprot.org/uniprot/P25917|https://www.uniprot.org/uniprot/P15391|https://www.uniprot.org/uniprot/F5H635|https://www.uniprot.org/uniprot/A0N0P9 |
T605 | 1147-1151 | Protein | denotes | CD20 | https://www.uniprot.org/uniprot/Q3C2E2|https://www.uniprot.org/uniprot/Q13963|https://www.uniprot.org/uniprot/P19437|https://www.uniprot.org/uniprot/P11836|https://www.uniprot.org/uniprot/P08984|https://www.uniprot.org/uniprot/B4DT24|https://www.uniprot.org/uniprot/A6NMS4 |
LitCovid-sample-PD-FMA
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T384 | 19-30 | Body_part | denotes | amino acids | http://purl.org/sig/ont/fma/fma82739 |
T385 | 49-60 | Body_part | denotes | amino acids | http://purl.org/sig/ont/fma/fma82739 |
T386 | 93-96 | Body_part | denotes | IgG | http://purl.org/sig/ont/fma/fma62872 |
T387 | 158-166 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
T388 | 248-259 | Body_part | denotes | lymphocytic | http://purl.org/sig/ont/fma/fma62863 |
T389 | 712-723 | Body_part | denotes | amino acids | http://purl.org/sig/ont/fma/fma82739 |
T390 | 1036-1041 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
T391 | 1308-1319 | Body_part | denotes | lymphocytic | http://purl.org/sig/ont/fma/fma62863 |
LitCovid-sample-PD-GO-BP-0
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T110 | 466-470 | http://purl.obolibrary.org/obo/GO_0001788 | denotes | ADCC |
T111 | 475-487 | http://purl.obolibrary.org/obo/GO_0006909 | denotes | phagocytosis |
T112 | 519-525 | http://purl.obolibrary.org/obo/GO_0040007 | denotes | growth |
T113 | 562-566 | http://purl.obolibrary.org/obo/GO_0001788 | denotes | ADCC |
T114 | 1017-1021 | http://purl.obolibrary.org/obo/GO_0001788 | denotes | ADCC |
T115 | 1483-1487 | http://purl.obolibrary.org/obo/GO_0001788 | denotes | ADCC |
LitCovid-sample-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T37 | 240-268 | Disease | denotes | chronic lymphocytic leukemia | http://purl.obolibrary.org/obo/MONDO_0004948 |
T38 | 510-518 | Disease | denotes | lymphoma | http://purl.obolibrary.org/obo/MONDO_0005062 |
T39 | 1117-1122 | Disease | denotes | tumor | http://purl.obolibrary.org/obo/MONDO_0005070 |
T40 | 1275-1295 | Disease | denotes | non‐Hodgkin lymphoma | http://purl.obolibrary.org/obo/MONDO_0018908 |
T41 | 1300-1328 | Disease | denotes | chronic lymphocytic leukemia | http://purl.obolibrary.org/obo/MONDO_0004948 |
LitCovid-sample-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T33 | 240-268 | Phenotype | denotes | chronic lymphocytic leukemia | http://purl.obolibrary.org/obo/HP_0005550 |
T34 | 510-518 | Phenotype | denotes | lymphoma | http://purl.obolibrary.org/obo/HP_0002665 |
T35 | 1117-1122 | Phenotype | denotes | tumor | http://purl.obolibrary.org/obo/HP_0002664 |
T36 | 1275-1295 | Phenotype | denotes | non‐Hodgkin lymphoma | http://purl.obolibrary.org/obo/HP_0012539 |
T37 | 1300-1328 | Phenotype | denotes | chronic lymphocytic leukemia | http://purl.obolibrary.org/obo/HP_0005550 |
LitCovid-sample-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T110 | 466-470 | http://purl.obolibrary.org/obo/GO_0001788 | denotes | ADCC |
T111 | 475-487 | http://purl.obolibrary.org/obo/GO_0006909 | denotes | phagocytosis |
T112 | 519-525 | http://purl.obolibrary.org/obo/GO_0040007 | denotes | growth |
T113 | 562-566 | http://purl.obolibrary.org/obo/GO_0001788 | denotes | ADCC |
T114 | 1017-1021 | http://purl.obolibrary.org/obo/GO_0001788 | denotes | ADCC |
T115 | 1483-1487 | http://purl.obolibrary.org/obo/GO_0001788 | denotes | ADCC |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T110 | 466-470 | http://purl.obolibrary.org/obo/GO_0001788 | denotes | ADCC |
T111 | 475-487 | http://purl.obolibrary.org/obo/GO_0006909 | denotes | phagocytosis |
T112 | 519-525 | http://purl.obolibrary.org/obo/GO_0040007 | denotes | growth |
T113 | 562-566 | http://purl.obolibrary.org/obo/GO_0001788 | denotes | ADCC |
T114 | 1017-1021 | http://purl.obolibrary.org/obo/GO_0001788 | denotes | ADCC |
T115 | 1483-1487 | http://purl.obolibrary.org/obo/GO_0001788 | denotes | ADCC |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T274 | 0-30 | Sentence | denotes | Mutation of the Fc amino acids |
T275 | 31-143 | Sentence | denotes | Alteration of the amino acids in the heavy‐chain Fc can alter IgG specificity and affinity for activating FcγRs. |
T276 | 144-424 | Sentence | denotes | The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele. |
T277 | 425-542 | Sentence | denotes | The mAb shows increased FcγRIII‐mediated ADCC and phagocytosis in vitro, and reduced lymphoma growth in mouse models. |
T278 | 543-922 | Sentence | denotes | Margetuximab is an ADCC‐enhanced IgG1 Fc‐engineered variant of the approved anti‐HER2 mAb trastuzumab in phase III for HER2‐expressing cancers.66, 93 Alteration of five amino acids (L235V, F243L, R292P, Y300L and P396L) enhanced binding to FcγRIIIa which also had the additional effect of decreasing binding to the inhibitory FcγRIIb, and thereby increased its A‐to‐I FcγR ratio. |
T279 | 923-1137 | Sentence | denotes | This was apparent when compared with unmodified trastuzumab the margetuximab showed enhanced ADCC against HER2+ cells in vitro and demonstrated superior antitumor effects in an HER2‐expressing tumor model in mice. |
T280 | 1138-1509 | Sentence | denotes | The anti‐CD20 ocaratuzumab is an Fc‐engineered IgG1 mAb in late‐stage clinical trials for the treatment of a range of cancers, including non‐Hodgkin lymphoma and chronic lymphocytic leukemia.94 Two Fc mutations, P247I and A339Q, conferred about 20‐fold increase in binding to both major allelic variants of FcγRIIIa and elicited sixfold greater ADCC than unmodified IgG1. |
T281 | 1510-1671 | Sentence | denotes | Thus, the engineering of the Fc domain or glycan for improved FcγRIIIa binding is a powerful tool to create more potent and clinically effective anticancer mAbs. |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T33 | 240-268 | Phenotype | denotes | chronic lymphocytic leukemia | http://purl.obolibrary.org/obo/HP_0005550 |
T34 | 510-518 | Phenotype | denotes | lymphoma | http://purl.obolibrary.org/obo/HP_0002665 |
T35 | 1117-1122 | Phenotype | denotes | tumor | http://purl.obolibrary.org/obo/HP_0002664 |
T36 | 1275-1295 | Phenotype | denotes | non‐Hodgkin lymphoma | http://purl.obolibrary.org/obo/HP_0012539 |
T37 | 1300-1328 | Phenotype | denotes | chronic lymphocytic leukemia | http://purl.obolibrary.org/obo/HP_0005550 |